Business Standard

Saturday, December 21, 2024 | 10:34 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Glenmark Pharmaceuticals enters into exclusive collaboration with SDC Pharmaceuticals

Image

Capital Market

To develop, manufacture and market ophthalmic products in the U.S. and Canada

Glenmark Pharmaceuticals announced it has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the U.S. and Canada. Under this agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.

It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) beginning in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the U.S. brand sales for the six products was approximately $1.7 billion for calendar year 2017.

 

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 22 2018 | 9:28 AM IST

Explore News